Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. Crucell focuses on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide. Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel and endemic and respiratory fields.
Corporate Press Releases:
9 February 2010
16 November 2009
3 November 2009
Organisationer och kommittéer jobbar med att minska antalet koleradrabbade i ett flyktingläger i...
Stock Quotes:
| Euronext: | € | 14.30 | 0.09 | (15 minute delay) | |
| NASDAQ: | $ | 19.19 | -0.07 | (15 minute delay) | |
| SWX: | CHF | 20.95 | 0.30 | (15 minute delay) |
More information on our share performance
E-MAIL THIS PAGE
PRINT THIS PAGE
© Crucell 2009 |
Disclaimer